切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2019, Vol. 07 ›› Issue (02) : 130 -134. doi: 10.3877/cma.j.issn.2095-5782.2019.02.009

所属专题: 文献

专题研究·肿瘤介入

TACE联合中药治疗不可切除肝细胞癌的研究进展
姚远1, 陈建建1, 周学良1, 焦德超1, 韩新巍1,()   
  1. 1. 450052 郑州大学第一附属医院介入放射科
  • 收稿日期:2019-03-02 出版日期:2019-05-01
  • 通信作者: 韩新巍

Research progress of TACE combined with traditional Chinese medicine in the treatment of unresectable hepatocellular carcinoma

Yuan Yao1, Jianjian Chen1, Xueliang Zhou1, Dechao Jiao1, Xinwei Han1,()   

  1. 1. Department of Interventional Radiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
  • Received:2019-03-02 Published:2019-05-01
  • Corresponding author: Xinwei Han
  • About author:
    Corresponding author: Han Xinwei, Email:
引用本文:

姚远, 陈建建, 周学良, 焦德超, 韩新巍. TACE联合中药治疗不可切除肝细胞癌的研究进展[J/OL]. 中华介入放射学电子杂志, 2019, 07(02): 130-134.

Yuan Yao, Jianjian Chen, Xueliang Zhou, Dechao Jiao, Xinwei Han. Research progress of TACE combined with traditional Chinese medicine in the treatment of unresectable hepatocellular carcinoma[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2019, 07(02): 130-134.

肝细胞癌(HCC)是我国常见的恶性肿瘤之一,而对于中晚期的肝癌患者,大多数已丧失外科手术切除的机会,此时经皮肝动脉化疗栓塞术(TACE)是目前为止的首选治疗方案。虽然它有着较好的临床疗效,但其不良反应也是临床医生所必须面对的问题。传统中药由于药性温和,不良反应较少,可以减少化疗药物的用量,提高机体的免疫力,故采用TACE联合中药治疗原发性肝癌也逐渐被临床医生所推广。文章旨在综述康莱特、榄香烯、槐耳颗粒及肝复乐等中药与TACE联合治疗HCC的应用情况和优势。

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China, and most patients with advanced HCC have lost the opportunity of surgical resection. At this time, TACE is by far the preferred treatment. It has better clinical efficacy, but its adverse reactions are also the problem that clinicians must face. Traditional Chinese medicine (TCM) is mild in nature and has few toxic and side effect, and it can reduce the dosage of chemotherapy drugs and improve the immunity of the body. Therefore, TACE combined with TCM for the treatment of HCC has been gradually promoted by clinicians. The purpose of this paper is to review the application and advantages of TACE combined with TCM such as Kanglaite, Elemene, Huaier and Ganfule.

[1]
Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy[J]. Pharmacol Ther,2017,173:106-117.
[2]
Singh S, Singh PP, Roberts LR,et al. Chemopreventive strategies in hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol,2014,11(1):45-54.
[3]
Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma[J]. Korean J Radiol,2009,10(5):425-434.
[4]
邱力戈,梁若斯,李勇,等.HepaSphere载药微球与碘油化疗栓塞大肝癌的不良反应比较[J].中华介入放射学电子杂志,2018,6(2):99-103.
[5]
苏莹莹,刘莹钰,张扬雨,等. 9种中药注射剂联合肝动脉插管化疗栓塞术治疗原发性肝癌的网状Meta分析[J].吉林大学学报(医学版),2016,42(6):1126-1131.
[6]
李戈,赵晨,思金华,等. 19种中药注射剂联合TACE治疗中晚期肝细胞癌的网状Meta分析[J].兰州大学学报(医学版),2016,42(3):57-63,72.
[7]
石芳毓,娄丽丽,谢吻,等.中药注射剂联合肝动脉插管栓塞化疗术治疗肝癌的网状Meta分析[J].中国实验方剂学杂志,2016,22(10):180-187.
[8]
Long ZX, Wang B, Tao D,et al. Clinical research on alternating hyperfraction radiotherapy for massive hepatocellular carcinoma[J]. Oncol Lett,2015,10(1):523-527.
[9]
Cai B, Ma LM, Nong SJ,et al. Β-elemene induced anticancer effect in bladder cancer through upregulation of PTEN and suppression of AKT phosphorylation[J]. Oncol Lett,2018,16(5):6019-6025.
[10]
Hu TL, Gao Y. Β-elemene against Burkitt's lymphoma via activation of PUMA mediated apoptotic pathway[J]. Biomed Pharmacother,2018,106:1557-1562.
[11]
Wu BQ, Jiang Y, Zhu F,et al. Demethylation effects of elemene on the GSTP1 gene in HCC cell line QGY7703[J]. Oncol Lett,2016,11(4):2545-2551.
[12]
Fu F, Wan YD, Wu T,et al. Kanglaite injection combined with hepatic arterial intervention for unresectable hepatocellular carcinoma: A meta-analysis[J]. J Cancer Res Ther,2014,10(Suppl 1):38-41.
[13]
Huang XL, Qin JJ, Lu S. Kanglaite stimulates anticancer immune responses and inhibits HepG2 cell transplantation-induced tumor growth[J]. Mol Med Rep,2014,10(4):2153-2159.
[14]
吴进录.康莱特注射液联合介入化疗治疗中晚期肝癌的临床观察[J].中国民间疗法,2015,23(12):60-61.
[15]
谢和平,李跃,王凤林,等.康莱特注射液联合肝动脉化疗栓塞术治疗原发性肝癌临床疗效[J].中成药,2018,40(12):2821-2823.
[16]
汪有锦.康莱特在肝癌介入治疗中的作用.中国中西医结合学会医学影像专业委员会第十五次全国学术大会[C].中国上海,2017.
[17]
张宜江,曹继华,徐兴东,等.康莱特联合介入化疗治疗原发性肝癌的临床研究[J].肿瘤药学,2017,7(1):104-108.
[18]
路大鹏,王玉强,赵卫林,等.康莱特联合肝动脉化疗栓塞术治疗肝癌的临床研究[J].世界临床医学,2017,11(5):70,72.
[19]
袁琴,王虚实,王君钰,等.榄香烯乳注射液对原发性肝癌患者免疫功能的影响[J].癌症进展,2016,14(7):664-666,670.
[20]
Wang QT, Zhang ZL, Xiong H,et al. Evaluation of the efficacy and safety of elemene in treating malignant pleural effusion caused by tumors: A PRISMA guided meta-analysis[J]. Medicine (Baltimore),2018,97(44):e12542.
[21]
Wu ZB, Wang T, Zhang YM,et al. Anticancer effects of β-elemene with hyperthermia in lung cancer cells[J]. Exp Ther Med,2017,13(6):3153-3157.
[22]
Mao YQ, Zhang JL, Hou L,et al. The effect of beta-elemene on alpha-tubulin polymerization in human hepatoma HepG2 cells[J]. Chin J Cancer Res,2013,25(6):770-776.
[23]
杨宇辉,吴清艺,黄印强,等.榄香烯联合肝动脉化疗栓塞治疗中晚期肝癌[J].中国卫生标准管理,2017,8(18):102-103.
[24]
王小璞,赵昌林,郑丹如.榄香烯注射液联合TACE治疗晚期原发性肝癌疗效观察[J].新中医,2017,49(5):87-90.
[25]
陈德连,江会红.榄香烯联合介入治疗中晚期肝癌患者的近期疗效[J].广州中医药大学学报,2016,33(1):27-30.
[26]
Zhao GS, Liu Y, Zhang Q,et al. Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma: Safety and efficacy[J]. Medicine(Baltimore),2017,96(29):e7589.
[27]
Zhang CS, Zhang JL, Li X,et al. Huaier aqueous extract induces hepatocellular carcinoma cells arrest in S phase via JNK signaling pathway[J]. Evid Based Complement Alternat Med,2015,2015:171356.
[28]
Bao HD, Liu P, Jiang K,et al. Huaier polysaccharide induces apoptosis in hepatocellular carcinoma cells through p38 MAPK[J]. Oncol Lett,2016,12(2):1058-1066.
[29]
Zheng JS, Li C, Wu X,et al. Huaier polysaccharides suppresses hepatocarcinoma MHCC97-H cell metastasis via inactivation of EMT and AEG-1 pathway[J]. Int J Biol Macromol,2014,64:106-110.
[30]
Zheng JS, Li C, Wu X,et al. Astrocyte elevated gene-1(AEG-1)shRNA sensitizes Huaier polysaccharide(HP)-induced anti-metastatic potency via inactivating downstream P13K/Akt pathway as well as augmenting cell-mediated immune response[J]. Tumour Biol,2014,35(5):4219-4224.
[31]
Hu ZD, Yang AL, Su GZ,et al. Huaier restrains proliferative and invasive potential of human hepatoma SKHEP-1 cells partially through decreased Lamin B1 and elevated NOV[J]. Sci Rep,2016,6:31298.
[32]
冯惠岗,梁奇伟,郭惠庄,等.甘草酸二铵联合槐耳颗粒治疗肝癌TACE术后栓塞综合征临床观察[J].中华介入放射学电子杂志,2016,4(4):197-201.
[33]
董德硕,刘兆玉.槐耳颗粒联合经肝动脉化疗栓塞术治疗肝细胞癌的研究进展[J].临床肝胆病杂志,2017,33(10):2021-2024.
[34]
董德硕,刘兆玉.基于真实世界肝动脉化疗栓塞术联合槐耳颗粒治疗肝细胞癌的临床研究[J].现代肿瘤医学,2018,26(5):741-746.
[35]
华向东,尚海,何忠野,等.槐耳颗粒联合经导管肝动脉化疗栓塞在原发性肝癌伴微血管侵犯根治术后的疗效分析[J].中国普外基础与临床杂志,2016,23(8):982-986.
[36]
尹剑,郭安红.肝动脉化疗栓塞联合肝复乐胶囊治疗原发性肝癌疗效及对血浆VEGF和内毒素的影响[J].现代中西医结合杂志,2018,27(24):2696-2699.
[37]
张继万,周建丽,张晓芳,等. Peg-IFN-α2a联合肝复乐胶囊对HbeAg阳性慢性乙型肝炎抗肝纤维化的疗效[J].武警医学,2017,28(3):257-260.
[38]
曹付春,韩雅莉,陈冰,等.地鳖纤溶蛋白对人脐静脉内皮细胞、肺癌、乳腺癌细胞VEGF和bFGF表达的影响[J].时珍国医国药,2011,22(8):1827-1829.
[39]
郝明志,陈武进,林海澜,等.肝动脉栓塞化疗联合肝复乐胶囊治疗晚期肝癌临床疗效观察[J].中南药学,2013,11(02):147-150.
[40]
周德江,何胜,翁敏.口服肝复乐联合经皮肝动脉栓塞化疗治疗中晚期原发性肝癌42例临床观察[J].医药前沿,2011,1(24):10-11.
[41]
Jiang YW, Yuan Q, Huang AB,et al. The synergistic mechanism of pemetrexed followed by kanglaite was due to KLT subsequently inhibiting the pemetrexed-activated MAPK signaling pathway[J]. Clin Lab,2015,61(10):1353-1363.
[42]
Liu Y, Zhang W, Wang XJ,et al. Antitumor effect of Kanglaite? injection in human pancreatic cancer xenografts[J]. BMC Complement Altern Med,2014,14:228.
[43]
Du X, Ye H, Zhang C,et al. Effect of kanglaite on rat cytochrome P450[J]. Pharm Biol,2014,53(7):995-1001.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 马旦杰, 黄品同, 徐琛, 周芳芳, 潘敏强. 超声造影LI-RADS系统联合甲胎蛋白对有无高危因素背景人群肝细胞癌的诊断价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(03): 288-296.
[3] 李敏, 杨世英, 高晓琴, 周丹, 唐筱, 张立婷. 维生素A与慢性肝病相关性研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(02): 65-70.
[4] 胡森焱, 徐冬, 方健, 谢冬冬, 王财庆. ICG荧光显影Laennec膜入路腹腔镜解剖性肝切除的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 513-516.
[5] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[6] 罗强, 黄河清, 李益明, 刘丽萍, 白思远. 康莱特注射液在晚期非小细胞肺癌化疗中的应用分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 280-283.
[7] 陈政, 叶庆旺, 赵东波, 石鑫, 吴建强, 余德才. 定位针引导下腹腔镜精准局部肝切除应用探索[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(02): 125-128.
[8] 莫鹏, 郭杏春, 梁秀娟, 王耀明. 超声引导与CT引导射频消融治疗肝细胞癌患者疗效及预后比较[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 151-154.
[9] 万菲, 任勇军. 原发性肝细胞癌肿瘤标志物研究进展[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(01): 77-81.
[10] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
[11] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[12] 陆知非, 华永飞, 姜哲康, 高过, 江寅, 王高卿. 初始不可切除肝癌转化治疗的影响因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(03): 268-274.
[13] 李军. "调神大法"治疗和干预围绝经期综合征[J/OL]. 中华针灸电子杂志, 2024, 13(02): 56-57.
[14] 倪管崟, 缪小赟, 丁家安, 田鹏程, 倪才方. 锥形束计算机断层扫描在肝癌介入诊疗中的应用进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(03): 256-260.
[15] 崔皓然, 顾俊鹏, 任伟新. 基于经导管动脉化疗栓塞联合治疗肝癌伴门静脉癌栓的进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(01): 64-69.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?